WallStSmart

Lineage, Inc. Common Stock (LINE)vsUcommune International Ltd (UK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 20463% more annual revenue ($5.37B vs $26.12M). LINE leads profitability with a -3.1% profit margin vs -144.9%. LINE earns a higher WallStSmart Score of 35/100 (F).

LINE

Avoid

35

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

UK

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 4.0Quality: 5.0
Piotroski: 3/9Altman Z: -31.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

UKSignificantly Overvalued (-79.0%)

Margin of Safety

-79.0%

Fair Value

$0.27

Current Price

$2.10

$1.83 premium

UndervaluedFair: $0.27Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

UK2 strengths · Avg: 9.5/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.7%3/10

Operating margin of 3.7%

Debt/EquityHealth
1.013/10

Elevated debt levels

UK4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.31M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-40.6%2/10

ROE of -40.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : UK

The strongest argument for UK centers on Price/Book, Debt/Equity.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : UK

The primary concerns for UK are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

LINE carries more volatility with a beta of 0.88 — expect wider price swings.

LINE is growing revenue faster at 0.8% — sustainability is the question.

LINE generates stronger free cash flow (186M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LINE scores higher overall (35/100 vs 31/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Ucommune International Ltd

REAL ESTATE · REAL ESTATE SERVICES · China

Ucommune International Ltd provides and manages agile office spaces in China and internationally. The company is headquartered in Beijing, China.

Want to dig deeper into these stocks?